In this prospective , randomised , open-label , parallel-group , multicentre trial conducted in Germany , patients with asthma received budesonide/formoterol 160 microg/4 .5 microg in a single inhaler ( Symbicort Turbuhaler with two inhalations twice daily for a 4-week run-in period .
